Journal Article (Review Article)

DKFZ-2023-00865

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Radiation Therapy Planning Using Fibroblast Activation Protein Inhibitor.

Koerber, S. A. (Last author)DKFZ*

2023
Elsevier Orlando, Fla. [u.a.]

This record in other databases:  

Please use a persistent id in citations: doi:10.1016/j.cpet.2023.03.003

Abstract: Computed tomography (CT), MR imaging, and PET with fluorodeoxyglucose F18/CT are commonly used for radiation therapy planning; however, issues including precise nodal staging on CT or false positive results on PET/CT limit their usability. Clinical trials using fibroblast activation protein ligands for additional imaging have provided promising results regarding staging and target volume delineation-particularly suitable for sarcoma, some gastrointestinal tumors, head and neck tumors, and lung and pancreatic cancer. Although further prospective trials are necessary to identify clinical settings for its application in radiation oncology, fibroblast activation protein inhibitor PET/CT indisputably represents an excellent opportunity for assisting radiotherapy planning.

Keyword(s): FAPI-PET/CT ; Oncologic management ; Radiation oncology ; Treatment planning

Note: #LA:E050# / 2023 Jul;18(3):369-380

---

Contributing Institute(s):

1. E050 KKE Strahlentherapie (E050)

Research Program(s):

1. 315 - Bildgebung und Radioonkologie (POF4-315) (POF4-315)

Appears in the scientific report 2023

---

Database coverage:
; Clarivate Analytics Master Journal List ; Emerging Sources Citation Index ; IF < 5 ; JCR ; SCOPUS ; Web of Science Core Collection

---